35 related articles for article (PubMed ID: 16471322)
1. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
Izumoto S; Tsuboi A; Oka Y; Suzuki T; Hashiba T; Kagawa N; Hashimoto N; Maruno M; Elisseeva OA; Shirakata T; Kawakami M; Oji Y; Nishida S; Ohno S; Kawase I; Hatazawa J; Nakatsuka S; Aozasa K; Morita S; Sakamoto J; Sugiyama H; Yoshimine T
J Neurosurg; 2008 May; 108(5):963-71. PubMed ID: 18447714
[TBL] [Abstract][Full Text] [Related]
2. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
[TBL] [Abstract][Full Text] [Related]
3. Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.
Chung DJ; Sharma S; Rangesa M; DeWolf S; Elhanati Y; Perica K; Young JW
Blood Adv; 2022 Mar; 6(5):1547-1558. PubMed ID: 35100339
[TBL] [Abstract][Full Text] [Related]
4. Cell-based immunotherapy approaches for multiple myeloma.
Kriegsmann K; Kriegsmann M; Cremer M; Schmitt M; Dreger P; Goldschmidt H; Müller-Tidow C; Hundemer M
Br J Cancer; 2019 Jan; 120(1):38-44. PubMed ID: 30518815
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell cancer vaccines: from the bench to the bedside.
Katz T; Avivi I; Benyamini N; Rosenblatt J; Avigan D
Rambam Maimonides Med J; 2014 Oct; 5(4):e0024. PubMed ID: 25386340
[TBL] [Abstract][Full Text] [Related]
6. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.
Tyler EM; Jungbluth AA; O'Reilly RJ; Koehne G
Blood; 2013 Jan; 121(2):308-17. PubMed ID: 23160468
[TBL] [Abstract][Full Text] [Related]
7. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
Van Driessche A; Berneman ZN; Van Tendeloo VF
Oncologist; 2012; 17(2):250-9. PubMed ID: 22291091
[TBL] [Abstract][Full Text] [Related]
8. Adoptive T-cell therapy for B-cell malignancies.
Hudecek M; Anderson LD; Nishida T; Riddell SR
Expert Rev Hematol; 2009 Oct; 2(5):517-32. PubMed ID: 21083018
[TBL] [Abstract][Full Text] [Related]
9. Studies of Wilms' Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore.
Lim CK; Goh YT; Hwang WY; Ho LP; Sun L
Biomark Insights; 2007 Aug; 2():293-8. PubMed ID: 19662212
[TBL] [Abstract][Full Text] [Related]
10. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
Tsuboi A; Oka Y; Nakajima H; Fukuda Y; Elisseeva OA; Yoshihara S; Hosen N; Ogata A; Kito K; Fujiki F; Nishida S; Shirakata T; Ohno S; Yasukawa M; Oji Y; Kawakami M; Morita S; Sakamoto J; Udaka K; Kawase I; Sugiyama H
Int J Hematol; 2007 Dec; 86(5):414-7. PubMed ID: 18192109
[TBL] [Abstract][Full Text] [Related]
11. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
[TBL] [Abstract][Full Text] [Related]
12. WT1 protein expression in childhood acute leukemia.
Kerst G; Bergold N; Gieseke F; Coustan-Smith E; Lang P; Kalinova M; Handgretinger R; Trka J; Müller I
Am J Hematol; 2008 May; 83(5):382-6. PubMed ID: 18161786
[TBL] [Abstract][Full Text] [Related]
13. New potential targets for treating myeloma bone disease.
Roodman GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6270s-6273s. PubMed ID: 17062712
[TBL] [Abstract][Full Text] [Related]
14. [Molecular quantitation of minimal residual disease in leukemia].
Tamaki H; Ogawa H
Nihon Naika Gakkai Zasshi; 2003 Jun; 92(6):956-62. PubMed ID: 12866439
[No Abstract] [Full Text] [Related]
15. WT1 expression level and clinical factors in multiple myeloma.
Hatta Y; Takeuchi J; Saitoh T; Itoh T; Ishizuka H; Iriyama N; Miyajima T; Kaneita Y; Saiki M; Yasukawa K; Yasukawa R; Kura Y; Nishinarita S; Sawada U; Horie T
J Exp Clin Cancer Res; 2005 Dec; 24(4):595-9. PubMed ID: 16471322
[TBL] [Abstract][Full Text] [Related]
16. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes.
Azuma T; Otsuki T; Kuzushima K; Froelich CJ; Fujita S; Yasukawa M
Clin Cancer Res; 2004 Nov; 10(21):7402-12. PubMed ID: 15534117
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
